Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.57 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29784735 | 1.00 | RAB9A (0.60) | RAB9AHSD17B1HSD17B2ALDH1A1GAA | |
| SCHEMBL6117229 | 0.87 | RAB9A (0.61) | RAB9AALDH1A1GAANPC1KDM4E | |
| SCHEMBL6371005 | 0.87 | RAB9A (0.75) | RAB9AALDH1A1GAANPC1SMN1; SMN2 | |
| SCHEMBL359701 | 0.86 | MAPT (0.56) | RAB9AHSD17B1HSD17B2ALDH1A1GAA | |
| SCHEMBL11653044 | 0.86 | RAB9A (0.60) | RAB9AALDH1A1GAANPC1SMN1; SMN2 | |
| SCHEMBL16137281 | 0.84 | EPHX1 (0.62) | RAB9AALDH1A1GAASMN1; SMN2KDM4E | |
| SCHEMBL5525112 | 0.84 | RAB9A (0.62) | RAB9AALDH1A1GAANPC1KDM4E | |
| SCHEMBL1285510 | 0.84 | KDM4E (0.54) | RAB9AALDH1A1GAANPC1SMN1; SMN2 | |
| SCHEMBL28817127 | 0.83 | ALDH1A1 (0.60) | RAB9AALDH1A1GAANPC1KDM4E | |
| SCHEMBL2191052 | 0.82 | HSD17B1 (0.75) | RAB9AHSD17B1HSD17B2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101786956-B | Method for deacylating N-acylated diphenylamine or ring-substituted derivatives thereof | MORIS CHEMICAL CO LTD | 2011-02-16 | — | — | CN | claimed |
| CN-101786956-A | Method for deacylating N-acylated diphenylamine or ring-substituted derivatives thereof | MORIS CHEMICAL CO LTD | 2010-07-28 | — | — | CN | claimed |
| US-20230331710-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331710-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD (CN) | 2023-10-19 | — | — | US | disclosed |
| EP-4194449-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| CN-108341774-B | Substituted quinolinone inhibitors | 首药控股(北京)股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-107531685-B | Compounds with antitumor activity | AB科学有限公司 | 2021-04-23 | — | — | CN | disclosed |
| CN-108069868-B | Method for preparing organic amide compound from aryl diazo tetrafluoroborate and nitrile | 湖南理工学院 | 2020-11-13 | — | — | CN | disclosed |
| EP-2914575-B1 | PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF | UNIV MICHIGAN REGENTS (US) | 2020-10-14 | — | — | EP | disclosed |
| US-9867803-B2 | IRE-1α inhibitors | SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) | 2018-01-16 | — | — | US | disclosed |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-11-16 | — | — | US | disclosed |
| WO-1997030035-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| EP-0276980-B1 | CHROMOGENIC FLUORAN COMPOUNDS | ESCO Company Limited Partnership (US) | 1992-09-23 | — | — | EP | disclosed |
| US-4910183-A | With an acidic developer | APPLETON PAPERS INC. (US) | 1990-03-20 | — | — | US | disclosed |
| US-4837210-A | PRESSURE SENSITIVE OR HEAT SENSITIVE ELEMENTS | APPLETON PAPERS INC. (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0276980-A2 | Chromogenic fluoran compounds | ESCO Company Limited Partnership (US) | 1988-08-03 | — | — | EP | disclosed |
| US-4600797-A | NITRATING AN AMINOBENZENE WHICH HAS A PROTECTEDD AMINO GROUP | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-15 | — | — | US | disclosed |
| EP-0049711-B1 | PROCESS FOR THE PRODUCTION OF NITRO-AMINO-BENZENES | BAYER AG (DE) | 1984-02-29 | — | — | EP | disclosed |
| US-4330473-A | FLUORAN COLOR-FORMER | YAMAMOTO KAGAKU GOSEI KABUSHIKI KAISHA (JP) | 1982-05-18 | — | — | US | disclosed |
| EP-0049711-A1 | Process for the production of nitro-amino-benzenes | BAYER AG (DE) | 1982-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331710-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | C9, CFB, C5 | RAB9A 2609/4885HSD17B1 458/4885HSD17B2 475/4885 |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | RAB9A 1146/4885HSD17B1 1046/4885HSD17B2 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.